Mercury Laboratories Limited is an established Indian pharmaceutical formulation company founded in **1962**. With over six decades of operational history, the company has carved a niche as a specialist in **Mother & Child Healthcare**, focusing specifically on the **Gynecology** and **Pediatrics** therapeutic segments. The company is currently undergoing a strategic transition, moving from a traditional domestic manufacturer to a technology-driven player targeting regulated global markets. --- ### **Core Therapeutic Focus and Product Strategy** The company operates exclusively within the **Pharmaceutical Products** segment, with a business model centered on the **in-house re-engineering** of drug formulations. * **Therapeutic Specialization:** Primary focus remains on **Mother & Child Healthcare**. * **Formulation & Development (F&D):** The R&D strategy emphasizes **newer delivery systems** to enhance the therapeutic value of existing molecules. This focus on delivery mechanisms allows the company to optimize its **material consumption ratio** and extend product life cycles. * **Innovation Pipeline:** The company is monitoring global shifts toward **biologics, biosimilars, and precision medicine**, particularly in high-growth areas like **obesity and diabetes**, which are projected to grow at **10%** annually. * **R&D Investment:** In **FY23**, the company recorded an R&D expenditure of **INR 0.85 Lakhs**, focusing on quality improvement and product range expansion. --- ### **Manufacturing Infrastructure and Asset Management** Mercury Laboratories operates two primary manufacturing units in **Vadodara, Gujarat**, both adhering to **WHO-GMP** and **ISO 9001:2008** standards. * **Unit 1 (Gorwa):** Serves as the corporate Head Office and the primary facility for general formulations. * **Unit 2 (Jarod):** Located on the Halol-Vadodara Road, this site is the hub for the company’s future growth. It features sustainable infrastructure, including a **solar roof-top** (representing a **INR 16.38 Lakhs** energy conservation investment) and an **auto DM water loop system**. * **Asset Depreciation Profile:** The company utilizes the **Straight Line Method** for depreciation. Key operational assets and their estimated useful lives include: | Asset Category | Useful Life | Asset Category | Useful Life | | :--- | :--- | :--- | :--- | | **Building** | **30 Years** | **Electrical / Furniture** | **10 Years** | | **Plant & Machinery** | **15 Years** | **Vehicles** | **8 Years** | | **Solar Panels** | **15 Years** | **Office Equipment** | **5 Years** | | **Laboratory Instruments** | **10 Years** | **Computers** | **3 Years** | --- ### **Strategic Expansion: The SVP Injectable Project** A cornerstone of the company’s forward-looking strategy is the expansion into the **Small Volume Parenteral (SVP)** market. * **Capacity Target:** A new injectable unit at the **Jarod** site designed for a capacity of **7.5 crore units** annually. * **Strategic Intent:** The plant is designed to meet the standards of **highly regulated international markets**, facilitating a shift toward higher-margin export geographies. * **Project Timeline & Delays:** Originally slated for **November 2025**, the commissioning has been deferred by **13 months** to **December 2026**. This delay is attributed to the need to comply with revised **Schedule M guidelines** issued by the Ministry of Health and Family Welfare. * **Leadership:** To spearhead this transition, **Mr. Jagdish Patil** was appointed as Head of Department for **Injectable Production** in **June 2024**. --- ### **Financial Performance and Market Dynamics** Following a period of record growth in **FY 2022-23**, the company has recently faced a phase of stagnant revenue and compressed profitability. **Three-Year Financial Summary:** | Metric (₹ in Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **75.10** | **75.56** | **75.33** | | **Net Profit (After Tax)** | **3.14** | **5.65** | **5.58** | | **Operating Profit Margin** | **10.77%** | **13.39%** | **-** | | **Return on Net Worth** | **11.12%** | **11.12%** | **12.98%** | * **Revenue Trends:** While domestic sales saw a slowdown in **FY 2024-25**, the **Export Business** grew by **11.39%**, continuing a trend of international expansion (which saw **100.18%** growth in **FY 2022-23**). * **Profitability Pressures:** The **44.38%** drop in net profit in the most recent fiscal year is attributed to rising **employee costs**, increased **selling expenses**, and the inability to fully pass through rising input costs to customers. * **Capital Allocation:** The company maintains a disciplined reserve policy, transferring **₹3.5 Crore** to General Reserves in both **FY23** and **FY24**. A dividend of **₹3.5 per share (35%)** was recommended for **FY 2023-24**. --- ### **Credit Profile and Liquidity** * **Credit Rating:** **CRISIL** reaffirmed a **'CRISIL BB+/Stable'** rating for the company’s **₹3 Crore** fixed deposits in July 2025. * **Debt Structure:** Short-term borrowings stood at **₹263.13 Lakhs** (March 2024), primarily consisting of a **Cash Credit Facility** (interest at **10.11% p.a.**) and vehicle loans (**8.50% p.a.**) from **HDFC Bank**. * **Fundraising:** The company has set a target to raise up to **₹5 Crore** via unsecured deposits from members to bolster working capital. --- ### **Governance and Human Capital** The company is overseen by a **6-member Board** with a focus on leadership continuity and professionalization. * **Key Leadership:** * **Mr. Rajendra R. Shah:** Managing Director and founder-director with **47 years** of experience; re-appointed until **March 31, 2026**. * **Mr. Sanjay Patel:** Appointed as **Chairman** effective **May 2025**. * **Mr. Saurabh Mittal:** Promoted to **Chief Operating Officer** and **VP – Marketing & Sales**, signaling a focus on operational integration. * **Workforce:** Total employee strength was **503** as of **March 2025**. The company recently integrated **four new labour codes**, resulting in a one-time exceptional impact of **₹39.49 Lakhs** related to gratuity computations. --- ### **Risk Framework and Mitigation** Mercury Laboratories operates within a rigorous risk management framework to navigate pharmaceutical and macroeconomic volatility. * **Regulatory Risks:** The company is adapting to the **Drugs, Medical Device and Cosmetics Bill 2023**, which imposes stricter quality standards. It is also defending a petition from the **Registrar of Companies** regarding past **Companies Act** violations; while the liability is currently unascertainable, the company views these as compoundable. * **Market Risks:** Exposure to the **National List of Essential Medicines (NLEM)** and price control revisions by the Health Ministry can impact net margins. * **Supply Chain:** Dependence on external **API** suppliers makes the company vulnerable to geopolitical shifts (e.g., **U.S.-China trade tensions**). The company is leveraging the **'Make in India'** and **PLI schemes** to pursue import substitution. * **Financial Risks:** * **Currency:** Uses **forward contracts** to hedge export invoicing. * **Credit:** Maintains long-term (**5–10 year**) relationships with clients; credit risk is currently rated as **Low**. * **Actuarial:** Manages risks related to salary escalation and potential legislative increases to **Gratuity Act** limits (beyond **INR 10,00,000**).